Isotechnika granted U.S. patent for immunosuppressive drug ISA247

By Lisa Kerner

Charlotte, N.C., June 30 - Isotechnika Inc. said it has been granted U.S. Patent No. 7,060,672 for its lead immunosuppressive drug, ISA247.

ISA247 is in an extension protocol of a Canadian phase 3 human clinical trial for the treatment of moderate to severe psoriasis as well as a North American phase 2b human clinical trial for the prevention of kidney graft rejection.

Isotechnika is an international biopharmaceutical company based in Edmonton, Alta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.